Caring Ambassadors Hepatitis C

Program Newsletter

June 2011


Clinical Trials, Cohort Studies, Pilot Studies


Safety and efficacy of peginterferon alpha plus ribavirin in patients with chronic hepatitis C and coexisting heart disease. Durante-Mangoni E, Iossa D, Pinto D, De Vincentiis L, Ragone E, Utili R. Dig Liver Dis. 2011 May;43(5):411-5.


Closure of Ascites Leaks with Fibrin Glue Injection in Patients with End-Stage Liver Disease. Sadik K, Laibstain S, Northup PG, Kashmer D, Bonatti HJ. J Laparoendosc Adv Surg Tech A. 2011 May 25. [Epub ahead of print]


Peginterferon with or without ribavirin has minimal effect on quality of life, behavioral/ emotional, and cognitive outcomes in children. Rodrigue JR, Balistreri W, Haber B, et al. Hepatology. 2011 May;53(5):1468-75. doi: 10.1002/hep.24248.


Patient-care practices associated with an increased prevalence of hepatitis C virus infection among chronic hemodialysis patients. Shimokura G, Chai F, Weber DJ, et al. Infect Control Hosp Epidemiol. 2011 May;32(5):415-24.


Prevalence of liver disease in veterans with bipolar disorder or schizophrenia. Fuller BE, Rodriguez VL, Linke A, Sikirica M, Dirani R, Hauser P. Gen Hosp Psychiatry. 2011 May-Jun;33(3):232-7. Epub 2011 May 6.


Open-label, ascending dose, prospective cohort study evaluating the antiviral efficacy of Rosuvastatin therapy in serum and lipid fractions in patients with chronic hepatitis C.

Patel K, Jhaveri R, George J, et al. J Viral Hepat. 2011 May;18(5):331-7. doi: 10.1111/j.1365-2893.2010.01310.x.


The hepatitis C self-management programme: a randomized controlled trial. Groessl EJ, Weingart KR, Stepnowsky CJ, Gifford AL, Asch SM, Ho SB. J Viral Hepat. 2011 May;18(5):358-68. doi: 10.1111/j.1365-2893.2010.01328.x.


Clinical experience with the treatment of hepatitis C infection in patients on opioid pharmacotherapy. Sasadeusz JJ, Dore G, Kronborg I, Barton D, Yoshihara M, Weltman M. Addiction. 2011 May;106(5):977-84. doi: 10.1111/j.1360-0443.2010.03347.x.


Diagnosis of depression in former injection drug users with chronic hepatitis C. Scott JD, Wang CC, Coppel E, Lau A, Veitengruber J, Roy-Byrne P. J Clin Gastroenterol. 2011 May-Jun;45(5):462-7.


Psychiatric and Substance Use Disorders among Methadone Maintenance Patients with Chronic Hepatitis C Infection: Effects on Eligibility for Hepatitis C Treatment. Batki SL, Canfield KM, Ploutz-Snyder R. Am J Addict. 2011 Jul;20(4):312-8. doi: 10.1111/j.1521-0391.2011.00139.x. Epub 2011 May 31.


Efficacy of re-treatment with pegylated interferon plus ribavirin combination therapy for patients with chronic hepatitis C in Japan. Oze T, Hiramatsu N, Yakushijin T, et al. J Gastroenterol. 2011 May 3. [Epub ahead of print]


Efficacy of pegylated interferon-α2a monotherapy in Japanese children with chronic hepatitis C. Tsunoda T, Inui A, Etani Y, et al. Hepatol Res. 2011 May;41(5):399-404. doi: 10.1111/j.1872-034X.2011.00789.x.


Efficacy and safety of peginterferon α-2a (40 kD) plus ribavirin among patients with chronic hepatitis C and earlier treatment failure to interferon and ribavirin: an open-label study in central and Eastern Europe. Husa P, Oltman M, Ivanovski L, Rehák V, Messinger D, Tietz A, Urbanek P. Eur J Gastroenterol Hepatol. 2011 May;23(5):375-81.


Th17 cells are increased with severity of liver inflammation in patients with chronic hepatitis C. Chang Q, Wang YK, Zhao Q, Wang CZ, Hu YZ, Wu BY. J Gastroenterol Hepatol. 2011 May 18. doi: 10.1111/j.1440-1746.2011.06782.x. [Epub ahead of print]


Basic and Applied Science, Pre-Clinical Studies


T Helper Type 1/T Helper Type 17-Related Cytokines in Chronic Hepatitis C Patients before and after Interferon and Ribavirin Therapy. Fathy A, Ahmed AS, Metwally L, Hassan A. Med Princ Pract. 2011;20(4):345-9. Epub 2011 May 11.



Single nucleotide polymorphism at exon 7 splice acceptor site of OAS1 gene determines response of hepatitis C virus patients to interferon therapy. El Awady MK, Anany MA, Esmat G, et al. J Gastroenterol Hepatol. 2011 May;26(5):843-50. doi: 10.1111/j.1440-1746.2010.06605.x.


Inhibition of Hepatitis C Virus 3a genotype entry through Glanthus Nivalis Agglutinin.

Ashfaq UA, Masoud MS, Khaliq S, Nawaz Z, Riazuddin S. Virol J. 2011 May 20;8:248.


Hepatitis C virus targets the T cell secretory machinery as a mechanism of immune evasion. Petrovic D, Stamataki Z, Dempsey E, et al. Hepatology. 2011 Jun;53(6):1846-53. doi: 10.1002/hep.24327. Epub 2011 May 2.


Expression profiles of genes associated with viral entry in HCV-infected human liver.

Nakamuta M, Fujino T, Yada R, et al. J Med Virol. 2011 May;83(5):921-7. doi: 10.1002/jmv.22042.


Hepatic Akt expression correlates with advanced fibrosis in patients with chronic hepatitis C infection. Huang JF, Chuang YH, Dai CY, et al. Hepatol Res. 2011 May;41(5):430-436. doi: 10.1111/j.1872-034X.2011.00786.x. Epub 2011 Apr 19.


Hepatitis C virus core protein induces fibrogenic actions of hepatic stellate cells via toll-like receptor 2. Coenen M, Nischalke HD, Krämer B, et al. Lab Invest. 2011 May 2. [Epub ahead of print]


Genetic determinants in hepatitis C virus-associated mixed cryoglobulinemia: role of polymorphic variants of BAFF promoter and Fcγ receptors. Gragnani L, Piluso A, Giannini C, et al. Arthritis Rheum. 2011 May;63(5):1446-51. doi: 10.1002/art.30274.


Distinct Functions of NS5A in HCV RNA Replication Uncovered by Studies with the NS5A Inhibitor BMS-790052. Fridell RA, Qiu D, Valera L, Wang C, Rose RE, Gao M. J Virol. 2011 May 18. [Epub ahead of print]


Estimation of inhibitory quotient using a comparative equilibrium dialysis assay for prediction of viral response to hepatitis C virus inhibitors. Mo H, Yang C, Wang K, et al. J Viral Hepat. 2011 May;18(5):338-48. doi: 10.1111/j.1365-2893.2010.01314.x.


Inhibition of full length Hepatitis C Virus particles of 1a genotype through small interference RNA. Ansar M, Ashfaq UA, Shahid I, et al. Virol J. 2011 May 2;8:203.


HIV/HCV Coinfection


Hepatitis C virus (HCV) treatment uptake and changes in the prevalence of HCV genotypes in HIV/HCV-coinfected patients. Medrano J, Resino S, Vispo E, et al. J Viral Hepat. 2011 May;18(5):325-30. doi: 10.1111/j.1365-2893.2010.01309.x.


Somatic symptoms and the association between hepatitis C infection and depression in HIV-infected patients. Yoon JC, Crane PK, Ciechanowski PS, et al. AIDS Care. 2011 May 11:1-11. [Epub ahead of print]


Low-density lipoprotein receptor genotyping enhances the predictive value of IL28B genotype in HIV/hepatitis C virus-coinfected patients. Pineda JA, Caruz A, di Lello FA, et al. AIDS. 2011 May 12. [Epub ahead of print]


Safety and efficacy of raltegravir in patients with HIV-1 and hepatitis B and/or C virus coinfection. Rockstroh J, Teppler H, Zhao J, et al. HIV Med. 2011 May 22. doi: 10.1111/j.1468-1293.2011.00933.x. [Epub ahead of print]


IL28B gene polymorphisms and viral kinetics in HIV/hepatitis C virus-coinfected patients treated with pegylated interferon and ribavirin. Rallón NI, Soriano V, Naggie S, et al.  AIDS. 2011 May 15;25(8):1025-33.


Impact of IL28B polymorphisms on response to peginterferon and ribavirin in HIV–hepatitis C virus-coinfected patients with prior nonresponse or relapse. Labarga P, Barreiro P, Mira JA, et al. AIDS. 2011 May 15;25(8):1131-3.


Treatment of hepatitis C virus (HCV) infection in patients coinfected with HIV in the HIV Outpatient Study (HOPS), 1999-2007. Vellozzi C, Buchacz K, Baker R, et al. J Viral Hepat. 2011 May;18(5):316-24. doi: 10.1111/j.1365-2893.2010.01299.x.


Treatment for hepatitis C virus with pegylated interferon-{alpha} plus ribavirin induces anti-atherogenic effects on cardiovascular risk biomarkers in HIV-infected and -uninfected patients. Masiá M, Robledano C, López N, Escolano C, Gutiérrez F. J Antimicrob Chemother. 2011 May 28. [Epub ahead of print]


Correlation between FIB4, liver stiffness and metabolic parameters in patients with HIV and hepatitis C virus co-infection. Bruno R, Sacchi P, Cima S, et al. Dig Liver Dis. 2011 Jul;43(7):575-8. Epub 2011 May 19.


Epidemiology, Diagnostics, and Miscellaneous Works


Irritability: an underappreciated side effect of interferon treatment for chronic hepatitis C? Blacklaws H, Gardner A, Usher K. J Clin Nurs. 2011 May;20(9-10):1215-24. doi: 10.1111/j.1365-2702.2010.03494.x. Epub 2011 Mar 3.


Partnering urban academic medical centers and rural primary care clinicians to provide complex chronic disease care. Arora S, Kalishman S, Dion D, et al. Health Aff (Millwood). 2011 Jun;30(6):1176-84. Epub 2011 May 19.


Immunological/virological peripheral blood biomarkers and distinct patterns of sleeping quality in chronic hepatitis C patients. de Almeida CM, de Lima TA, Castro DB, et al. Scand J Immunol. 2011 May;73(5):486-95. doi: 10.1111/j.1365-3083.2011.02518.x.


Current strategies for managing providers infected with bloodborne pathogens. Turkel S, Henderson DK. Infect Control Hosp Epidemiol. 2011 May;32(5):428-34.


Electronic matching of HIV/AIDS and hepatitis C surveillance registries in three states.

Speers S, Klevens RM, Vonderwahl C, et al. Public Health Rep. 2011 May-Jun;126(3):344-8.


Breaking Bad News: The Patient's Viewpoint. Munoz Sastre MT, Sorum PC, Mullet E. Health Commun. 2011 May 17:1-7. [Epub ahead of print]


Hepatitis C virus infection among adolescents and young adults --- Massachusetts, 2002--2009. Centers for Disease Control and Prevention (CDC). MMWR Morb Mortal Wkly Rep. 2011 May 6;60(17):537-41.



Liver Cancer


Impact of diabetes mellitus on incidence of hepatocellular carcinoma in chronic hepatitis C patients treated with interferon-based antiviral therapy. Hung CH, Lee CM, Wang JH, Hu TH, Chen CH, Lin CY, Lu SN. Int J Cancer. 2011 May 15;128(10):2344-52. doi: 10.1002/ijc.25585.


Improvement of long-term outcomes in hepatitis C virus antibody-positive patients with hepatocellular carcinoma after hepatectomy in the modern era. Shirabe K, Takeishi K, Taketomi A, Uchiyama H, Kayashima H, Maehara Y. World J Surg. 2011 May;35(5):1072-84.


Risk factors for hepatocellular carcinoma in a cohort infected with hepatitis B or hepatitis C. Walter SR, Thein HH, Gidding HF, Amin J, Law MG, George J, Dore GJ. J Gastroenterol Hepatol. 2011 May 26. doi: 10.1111/j.1440-1746.2011.06785.x. [Epub ahead of print]